Who are KITE-753's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Relma-cel, IL-7/IL-15 pre-treated CD19 cells, cART, rondecabtagene autoleucel, bb2121, Low-dose CAR-T cells group.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/kite-753.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

KITE-753 — Competitive Intelligence Brief

KITE-753 (KITE-753) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CAR-T cell therapy. Area: Oncology.

phase 3 CAR-T cell therapy Tumor-associated antigen (specific target not publicly disclosed in detail) Oncology Biologic Live · refreshed every 30 min

Target snapshot

KITE-753 (KITE-753) — Kite, A Gilead Company. KITE-753 is a CAR-T cell therapy that redirects a patient's own T cells to recognize and kill cancer cells expressing a specific tumor antigen.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
KITE-753 TARGET	KITE-753	Kite, A Gilead Company	phase 3	CAR-T cell therapy	Tumor-associated antigen (specific target not publicly disclosed in detail)
Relma-cel	Relma-cel	Shanghai Ming Ju Biotechnology Co., Ltd.	marketed	CAR-T cell therapy
IL-7/IL-15 pre-treated CD19 cells	IL-7/IL-15 pre-treated CD19 cells	jiangjingting	marketed	CAR-T cell therapy	CD19
cART	cART	LI Taisheng	marketed	CAR-T cell therapy	Tumor-associated antigen (specific target depends on formulation)
rondecabtagene autoleucel	rondecabtagene autoleucel	Lyell Immunopharma, Inc.	phase 3	CAR-T cell therapy	Mesothelin (MSLN)
bb2121	bb2121	Celgene	phase 3	CAR-T cell therapy	BCMA (B-cell maturation antigen)
Low-dose CAR-T cells group	Low-dose CAR-T cells group	Guangzhou Women and Children's Medical Center	phase 3	CAR-T cell therapy	Tumor-associated antigens (specific target antigen not specified)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CAR-T cell therapy class)

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · 3 drugs in this class
Chongqing Precision Biotech Co., Ltd · 2 drugs in this class
Guangzhou Women and Children's Medical Center · 2 drugs in this class
Sinocelltech Ltd. · 2 drugs in this class
Gruppo Italiano Malattie EMatologiche dell'Adulto · 1 drug in this class
Guangzhou Bio-gene Technology Co., Ltd · 1 drug in this class
Celyad Oncology SA · 1 drug in this class
Janssen Scientific Affairs, LLC · 1 drug in this class
EdiGene Inc. · 1 drug in this class
Hrain Biotechnology Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). KITE-753 — Competitive Intelligence Brief. https://druglandscape.com/ci/kite-753. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab